Maxvax raises ￥400M+ Series D to boost vaccine pipeline

In October 2025, Chengdu Maxvax Biotechnology Co., Ltd. ("Maxvax") announced the completion of its Series D financing round, raising over 400 million RMB. This round was jointly invested by IDG Capital, Shenzhen Capital Group, and Ringpu Pharmaceutical.

The raised capital will be primarily used to support the pre-launch preparations for its recombinant shingles vaccine, the Phase III clinical study of its recombinant respiratory syncytial virus (RSV) vaccine, the preclinical development of several subsequent innovative vaccine pipelines, and international collaboration efforts.

Dr. Chen Dexiang, founder of Maxvax, stated: "We extend our sincere gratitude to existing shareholders such as IDG and Shenzhen Capital Group for their recognition and continued investment, while also warmly welcoming Ringpu Pharmaceutical as a new shareholder. The company will utilize the funds raised in this round to increase R&D investment, accelerate the clinical development and market readiness of our shingles and respiratory syncytial virus (RSV) vaccines, with the goal of achieving commercialization within the next 1-2 years to contribute to global health."